Eli Lilly’s existing October 2024 material transfer agreement with Peptron remains limited to non-exclusive feasibility research on applying SmartDepot sustained-release microsphere technology to select peptide candidates, with no commercial licensing terms or technology transfer announced as of mid-2026. Joint studies continue on track across multiple assets but have not yet produced the data packages, regulatory clarity, or negotiation milestones typically required for a binding deal. The compressed window to the October 7 resolution date leaves little room for completing formulation work, internal reviews, and contract execution, especially while Lilly explores competing long-acting and oral obesity approaches. Traders therefore assign an 84.5% implied probability to “No,” reflecting the early-stage status of the collaboration and the absence of catalysts that would accelerate a full commercial license.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया16% संभावना
$11,264 वॉल्यूम
$11,264 वॉल्यूम
6 अक्टू, 2026
16% संभावना
$11,264 वॉल्यूम
$11,264 वॉल्यूम
6 अक्टू, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 material transfer agreement with Peptron remains limited to non-exclusive feasibility research on applying SmartDepot sustained-release microsphere technology to select peptide candidates, with no commercial licensing terms or technology transfer announced as of mid-2026. Joint studies continue on track across multiple assets but have not yet produced the data packages, regulatory clarity, or negotiation milestones typically required for a binding deal. The compressed window to the October 7 resolution date leaves little room for completing formulation work, internal reviews, and contract execution, especially while Lilly explores competing long-acting and oral obesity approaches. Traders therefore assign an 84.5% implied probability to “No,” reflecting the early-stage status of the collaboration and the absence of catalysts that would accelerate a full commercial license.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
बाज़ार खुला: May 5, 2026, 8:02 PM ET
वॉल्यूम
$11,264समाप्ति तिथि
7 अक्टू, 2026बाज़ार खुला
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 material transfer agreement with Peptron remains limited to non-exclusive feasibility research on applying SmartDepot sustained-release microsphere technology to select peptide candidates, with no commercial licensing terms or technology transfer announced as of mid-2026. Joint studies continue on track across multiple assets but have not yet produced the data packages, regulatory clarity, or negotiation milestones typically required for a binding deal. The compressed window to the October 7 resolution date leaves little room for completing formulation work, internal reviews, and contract execution, especially while Lilly explores competing long-acting and oral obesity approaches. Traders therefore assign an 84.5% implied probability to “No,” reflecting the early-stage status of the collaboration and the absence of catalysts that would accelerate a full commercial license.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
वॉल्यूम
$11,264समाप्ति तिथि
7 अक्टू, 2026बाज़ार खुला
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s existing October 2024 material transfer agreement with Peptron remains limited to non-exclusive feasibility research on applying SmartDepot sustained-release microsphere technology to select peptide candidates, with no commercial licensing terms or technology transfer announced as of mid-2026. Joint studies continue on track across multiple assets but have not yet produced the data packages, regulatory clarity, or negotiation milestones typically required for a binding deal. The compressed window to the October 7 resolution date leaves little room for completing formulation work, internal reviews, and contract execution, especially while Lilly explores competing long-acting and oral obesity approaches. Traders therefore assign an 84.5% implied probability to “No,” reflecting the early-stage status of the collaboration and the absence of catalysts that would accelerate a full commercial license.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न